Quantcast
Last updated on April 24, 2014 at 16:01 EDT

Latest Tenofovir Stories

2014-04-18 23:04:22

Markets Research Reports.biz added deep and professional market research reports on "HIV Therapeutics Market To 2019" Industry Analysis and Overview. Visit: http://www.marketresearchreports.biz/analysis/193009 (PRWEB) April 18, 2014 The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress...

2014-03-06 08:30:17

Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March 6, 2014 /PRNewswire/ -- Today Boehringer Ingelheim announced results from STARTVerso(®)4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

New Technology Combining Contraception, HIV And Herpes Simplex Virus-2 Prevention
2013-11-12 12:19:08

CONRAD Multipurpose prevention technologies featured at AAPS Annual Meeting and International Conference on Family Planning CONRAD Head of drug delivery, Meredith Clark, PhD, today presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas. This multipurpose prevention technology (MPT) can remain in the...

2013-10-10 12:29:23

BETHLEHEM, Pa., Oct. 10, 2013 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO) , has completed the clinical trial manufacturing of vaginal rings with a unique architecture, essentially a powdered filled tube. Designed to deliver the pro-drug tenofovir disoproxil fumarate for 30 days, the device is aimed at HIV prevention and joins several other microbicide delivery approaches under development. The ring provided complete...

HIV Prevention For Women Through New Intravaginal Ring
2013-09-28 05:09:09

April Flowers for redOrbit.com - Your Universe Online The HIV/AIDS epidemic often has a woman's face because the proportion of women infected with HIV has been on the rise for a decade. For example, in sub-Saharan Africa, women constitute 60 percent of people living with disease. Preventative drugs are available, but they are often ineffective, especially in light of financial and cultural barriers in developing nations. The answer, according to a new study published in the Proceedings...

Tenofovir Helps Prevent Contraction Of HIV
2013-06-13 13:20:00

Brett Smith for redOrbit.com - Your Universe Online New research from the Centers for Disease Control and Prevention suggests that a daily pill can prevent the contraction of HIV for intravenous drug users. The four-year study, which was published in The Lancet, boosts the argument of those advocating a preventative strategy called “¯pre-exposure prophylaxis, or PrEP. "This is a significant step forward for HIV prevention," Jonathan Mermin, a CDC spokesman who was not...

2013-06-12 16:26:31

AVAC Calls for Accelerated Action to Get PrEP to Those Who Can Benefit From It NEW YORK, June 12, 2013 /PRNewswire-USNewswire/ -- Results from the Bangkok Tenofovir Study published online today in The Lancet provide additional evidence that daily oral tenofovir-based pre-exposure prophylaxis (PrEP) reduces HIV infection risk when taken consistently. The results from the study--the first conducted among people who inject drugs--are consistent with previous studies among men and women...

2013-04-04 12:01:05

A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE. The study, led by researchers with the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), tested a reduced glycerin formulation of tenofovir gel, and has spurred the development of an expanded safety study of the gel, expected to launch later this...

2013-03-04 12:28:38

VOICE Results Underscore Need for Clear, US-Based PrEP Implementation Agenda ATLANTA, March 4, 2013 /PRNewswire-USNewswire/ -- The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women's health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at...